XTEN-peptide and protein half-life extension
Vladimir Podust
Director of Analytical Chemistry, Amunix
At Amunix, we have developed a novel half-life extension technology based on XTEN, a hydrophilic, unstructured polypeptide which can be recombinantly fused or chemically conjugated to other peptides, proteins, and small molecules. We have applied our XTEN technology platform to targets in a wide range of therapeutic areas, creating new protein pharmaceuticals characterized by improved efficacy, safety, and dosing.